ٍٍSofosbuvir/Simeprevir/Daclatasvir/Ribavirin and HCV Genotype 4-infected Egyptian Experienced Participants
ٍٍSofosbuvir/Simeprevir/Daclatasvir/Ribavirin and HCV Genotype 4-infected Egyptian Experienced Participants
Experienced participants who had HCV GT4 infection were treated with
 Sofosbuvir/Simeprevir/Daclatasvir/Ribavirin (SOF/SMV/DCV/RBV)
Experienced participants, who had chronic infection with HCV GT4 , and failed prior DAA
 treatments, SOF/DCV (71/92) or SOF/SMV (15/92) or SOF/pegylated interferon/RBV (2/92) or
 SOF/RBV (4/92) were enrolled in the current study.

 In the present study, the regimen used was designed by the combination of triple DAAs with
 different mechanisms of action and non-overlapping resistance profiles, SOF/SMV/DCV, plus
 RBV.
Inclusion Criteria:

 -  Experienced Egyptian participants with HCV GT4 infection who had failed prior DAA
 treatments [SOF/DCV or SOF/SMV or SOF/pegylated interferon/RBV or SOF/RBV]

 -  Fibrosis-4 score in non-cirrhotic participants is <1.45-3.25: (None or moderate
 fibrosis)

 -  Fibrosis-4 score in cirrhotic participants is >3.25: (Advanced fibrosis or cirrhosis)

 Exclusion Criteria:

 -  HCV coinfected with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)

 -  had any liver disease other than chronic HCV GT4 infection.

 -  had a history of liver decompensation

 -  serum a-fetoprotein (AFP) > 100 ng/ml

 -  evidence of hepatocellular carcinoma

 -  major severe illness such as respiratory, renal, heart failure or autoimmune disease

 -  non-compliance with treatment.